To determine the receptors involved in prostate tumor cell recognition and their contribution, IL-2/IL-15-activated PBMCs from healthy donors were pre-incubated with blocking antibodies against each NK cell receptor, and then used in CD107 degranulation assay against prostate cell lines or K562 as positive control. The gene discussed is IL15; the disease is prostate neoplasm.